Patents Assigned to KALLYOPE, INC.
  • AMPK activators
    Patent number: 11851429
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: December 26, 2023
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He, Ann Weber, Nancy Thornberry, Lisa Krug, Paul Richards, Brett Lauring
  • GPR119 agonists
    Patent number: 11512065
    Abstract: This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: November 29, 2022
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He, Christopher Moyes
  • AMPK activators
    Patent number: 11407768
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists, super agonists, full agonists, or partial agonists.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: August 9, 2022
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He
  • AMPK activators
    Patent number: 11279702
    Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: March 22, 2022
    Assignee: KALLYOPE, INC.
    Inventors: Iyassu Sebhat, Shuwen He